10.30
-0.48%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mink Therapeutics
From its filings with the US Securities and Exchange Commission
Mink Therapeutics is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker INKT. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $12.5m. At that date it held total assets of $14.2m and shareholders' equity of −$14.2m.
MiNK Therapeutics, Inc. (“we,” “our,” or “MiNK”) is focused on developing innovative treatments for cancer and immune-mediated diseases using allogeneic, ex-vivo expanded invariant natural killer T ("iNKT") cells. Amid a broader industry renaissance in innate immunity—highlighted by surging investment and clinical activity in NK, γδ T, and iNKT-based therapies—iNKT cells represent a distinct T cell (“T”) population that uniquely bridges innate and adaptive immunity. They combine durable memory responses characteristic of adaptive T cells with rapid, MHC-independent rapid cytolytic capabilities of natural killer ("NK") cells. This dual functionality enables direct tumor killing via CD1d and stress ligands, potent orchestration of the tumor microenvironment through activation of dendritic cells and NK cells, elimination of immunosuppressive myeloid populations, and restoration of exhausted T-cell function—all while naturally suppressing graft-versus-host disease ("GvHD"). This unique combination positions iNKT cells as an optimal platform for allogeneic therapy, given their natural homing capabilities, tumor clearance potential, and efficacy against infected cells.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Oct 2021
- Employees
- 37
- Website
- minktherapeutics.com ↗
- Head office
- 149 FIFTH AVENUE, NEW YORK, NY, 10010
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Dr. Garo ArmenChairman of the Board, Co-Founder, since 2017$344,320
- Dr. Jennifer BuellPresident, Chief Executive Officer, Co-Founder, Director, since 2021$798,686
- Ms. Christine KlaskinTreasurer$29,822
- Dr. John HolcombDirector
- Mr. Peter BehnerIndependent Director$61,500
- Mr. Brian CorveseIndependent Director$71,500
- Dr. Robert KadlecIndependent Director$33,160
- Ms. Barbara RyanIndependent Director$71,000
- Mr. Ulf WiinbergIndependent Director$60,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Mink Therapeutics focuses on allogeneic iNKT cell therapies for cancer treatment with scalable manufacturing.
- AgenT-797 is an off-the-shelf allogeneic iNKT cell therapy with durable memory responses.
- MiNK-413 is an IL-15 armored CAR-iNKT program targeting immune-mediated diseases.
Weaknesses
- Mink Therapeutics has only 37 employees, limiting operational capacity.
- The company's clinical stage status indicates early development phase challenges.
- The IPO on 15 October 2021 shows limited market history and financial stability.
Opportunities
- The US biotechnology sector offers growth potential for innovative cancer therapies.
- Allogeneic iNKT cell therapies could expand to treat immune-mediated diseases.
- Mink Therapeutics can leverage the New York City biotech hub for partnerships.
Threats
- Competition in the US Health Care sector may impact market share.
- Regulatory hurdles in biopharmaceutical development pose risks.
- The biotechnology industry faces high R&D costs and funding challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.